Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Eaton Corporation plc (ETN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Eaton Corporation plc — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $356.44 (market cap $9.43B), while Eaton Corporation plc trades at $458 (market cap $172.82B). The key difference: Eaton Corporation plc is far larger — about 18.3× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Eaton Corporation plc pays a 0.99% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | ETN | |
|---|---|---|
Market Cap | $9.43B | $172.82B |
Sector | Health | Technology |
52-Week High | $356.25 | $459.29 |
52-Week Low | $241.71 | $315.82 |
Enterprise Value | $9.18B | $193.45B |
Dividend Yield | — | 0.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Rad Laboratories (BIO) trades at $362.08, up 2.13% daily, near its 52-week high. The stock shows a bullish technical trend with strong moving averages, though RSI indicates overbought conditions. Fundamentally, Q2 2026 earnings beat estimates with EPS of $2.62 versus $1.75 expected, and revenue remains stable around $2.6 billion. Net income turned positive in 2025 after prior losses, with a current net margin of 29.41%. Analyst consensus is Buy with a $350 price target, and institutional holdings increased, as noted by Amundi's 1,763.4% stake growth per SEC filing on August 5, 2026.
Outlook is cautiously optimistic with solid earnings recovery and institutional support, but risks include high P/E of 43.39, potential overvaluation, and reliance on academic research markets. Investors should weigh strong profitability against valuation concerns and monitor upcoming Q3 earnings for sustained growth.
Eaton Corporation (ETN) trades at $459.96, up 3.37% with strong technical momentum and bullish moving average signals. The company delivered three consecutive quarterly earnings beats, with Q2 2026 EPS of $3.15 beating expectations of $3.07. Revenue growth continues with 2026 projections at $30.0 billion, though net profit margin is expected to compress to 12.75%. Recent news highlights Eaton's $7 million Air Force contract for quantum computing grid security and strong AI infrastructure demand.
Outlook remains positive with analyst consensus price target of $499.75 (8.6% upside) and unanimous bullish ratings (26 Buy, 0 Sell). Key risks include premium valuation (P/E 45.31) and execution challenges in meeting raised 2026 guidance. The stock's proximity to 52-week highs suggests near-term consolidation potential despite strong fundamental momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Eaton Corporation plc
Eaton is a global power management company providing energy-efficient solutions for electrical, aerospace, and industrial sectors. It focuses on improving sustainability through intelligent power technology.
Read more on ETN →
